COVID-19 in cancer patients

Seneviratne, Suranjith L.; Wijerathne, Widuranga; Yasawardene, Pamodh; Somawardana, Buddhika

doi:10.1093/trstmh/trac015

Cited by 13 publications

(18 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this environment, people have become conscious of physical distancing and putting on masks. The COVID-19 pandemic has posed pressing challenges in providing health care to cancer patients (1).Due to lockdowns, a large part of screening and diagnosis has had to be postponed (2,3). During the pandemic, the cancer mortality rate was higher than that of the new coronary pneumonia (4), and an advanced clinical stage and treatment interruption were risk factors (5).…”

Section: Introductionmentioning

confidence: 99%

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

Yan

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe 2019 novel coronavirus disease (COVID-19) strongly affects health care activities in countries around the world. The diagnosis and treatment of cancer have also been involved, and elderly head and neck squamous carcinoma is one of them. This study aimed to assess the impact of COVID-19 on elderly patients with head and neck squamous cell carcinoma (HNSCC) in our center.MethodsThis retrospective study analyzed the clinical characteristics of 400 HNSCC patients over 65 years of age, calculated their treatment interruption rates, and compared the time of delayed diagnosis.ResultsThe rate of elderly patients with HNSCC with a delayed diagnosis was higher in the “during COVID-19 pandemic” group (DCOV19 group) than in the “during COVID-19 pandemic” group (BCOV19 group), and the difference was statistically significant (p=0.0017). There was a substantial difference in the rate of treatment interruption between the two groups (p=0.002).ConclusionsThis is the first study to explore the effect of the COVID-19 pandemic on visits and treatment interruptions in elderly patients with HNSCC. The current impact of the COVID-19 pandemic on HNSCC treatment has resulted in reductions and delays in diagnosing cancer and providing treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

Yan

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Thus, proactive measures need to be undertaken to reduce the frequency of hospital visits of patients with cancer during the ongoing viral pandemic. 85,173 Thus, strict protection and precautions are needed for cancer patients to avoid SARS-CoV-2 infection. 174,175 Moreover, the frequency of therapeutic and radiotherapy sessions must be set properly to restrict the chances of COVID-19 infection during radiotherapy.…”

Section: Care For Cancer Patients Under Radiotherapy Surgery and Chem...mentioning

confidence: 99%

“…At the same time, the TNF‐receptor family, which includes RANKL, can regulate NF‐κB levels. Such shared pathway triggers a nexus of signaling components affecting both the diseases 66,85–87 …”

Section: Unveiling the Lethal Convergence: Exploring The Intersection...mentioning

confidence: 99%

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Ghosh,

Tabassum,

Basu

2023

MedComm – Oncology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic brought about unprecedented challenges to global healthcare systems. Among the most vulnerable populations are cancer patients, who face dilemmas due to their compromised immune systems and the intricate interplay with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. This comprehensive review delves into the multifaceted relationship between COVID‐19 and cancer. Through an analysis of existing literature and clinical data, this review unravels the structural intricacies of the virus and examines its profound implications for cancer patients, thereby bridging the knowledge gap between virology and oncology. The review commences with an introduction regarding the COVID‐19 pandemic and cancer. It then transitions into a detailed examination of the SARS‐CoV‐2 virus and its variants such as Alpha (PANGO lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529 lineage). Subsequently, an insightful analysis of the impact of COVID‐19 on major cancer types (viz., Lung, Colon, Brain, and gastrointestinal cancer) is elaborated. Finally, the therapeutic avenues, oncological care, and management are discussed. The nexus between COVID‐19 and cancer adds a layer of complexity to patient care, emphasizing the importance of tailored approaches for those grappling with both conditions. Amid the landscape defined by the evolving viral strains, this review navigates through the multifaceted implications of COVID‐19 on cancer patients and underscores the significance of integrating virology and oncology.

show abstract

“…The emergence of SARS-CoV-2 variants has led to further changes in disease manifestations and the effectiveness of vaccines. 13 Shortened vaccination schedules and provision of a third dose of vaccines has been proposed for patients with cancer. In the present article, existing knowledge (as at the end of September 2021) on the effectiveness, immunogenicity and safety of COVID-19 vaccines in patients with cancer is discussed.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccination in cancer patients: a narrative review

et al. 2022

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected over 220 million individuals worldwide, and has been shown to cause increased disease severity and mortality in patients with active cancer versus healthy individuals. Vaccination is important in reducing COVID-19-associated morbidity and mortality. Thus, the aim of this article was to review the existing knowledge on effectiveness, immunogenicity and safety of COVID-19 vaccines in patients with cancer. Fifty-four articles were included following a search of PubMed and Google Scholar databases for studies published between January 2020 and September 2021 that investigated humoral and cell-mediated immune responses following COVID-19 vaccination in patients with cancer. Immunogenicity of vaccines was found to be lower in patients with cancer versus healthy individuals, and humoral immune responses were inferior in those with haematological versus solid cancers. Patient-, disease-, and treatment-related factors associated with poorer vaccine responses should be identified and corrected or mitigated when possible. Consideration should be given to offering patients with cancer second doses of COVID vaccine at shorter intervals than in healthy individuals. Patients with cancer warrant a third vaccine dose and must be prioritized in vaccination schedules. Vaccine adverse effect profiles are comparable between patients with cancer and healthy individuals.

show abstract

COVID-19 in cancer patients

Cited by 13 publications

References 165 publications

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

COVID‐19 and cancer: Dichotomy of the menacing dilemma

COVID-19 vaccination in cancer patients: a narrative review

Contact Info

Product

Resources

About